Devang Vallabhdas Kantesaria
Chief Executive Officer at Valley Forge Capital Management LP
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Eric S. Lander | M | 67 |
Massachusetts Institute of Technology
| 34 years |
| John Deutch | M | 85 |
Massachusetts Institute of Technology
| 34 years |
| John B. Vander Sande | M | 79 |
Massachusetts Institute of Technology
| 32 years |
| Bob J. McParland | M | - |
TL Ventures, Inc.
 TL Ventures, Inc. Investment ManagersFinance TL Ventures Inc (TL Ventures) is a venture capital subsidiary of Safeguard Scientifics, Inc. founded in 1988 by Robert Keith. The firm is headquartered in Wayne, Pennsylvania. | 23 years |
| Benjamin E. Silverman | M | - |
Valley Forge Capital Management LP
 Valley Forge Capital Management LP Investment ManagersFinance Valley Forge Capital Management LP (VFCM) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Wayne, Pennsylvania. The firm was founded by Devang Kantesaria in 2009 as Valley Forge Advisors LP, the successor entity to Valley Forge Advisors LLC. VFCM provides advisory services on a discretionary basis to privately offered pooled investment vehicles, which are intended for investment by certain investors that are accredited investors as defined under federal securities law. | 10 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dale Ritter | M | 73 |
Inotek Pharmaceuticals Corp.
 Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | - |
| Michael Loberg | M | 76 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 8 years |
| Mohsin Ansari | M | - |
Massachusetts Institute of Technology
| 6 years |
| Tidhar Shalon | M | 59 |
Massachusetts Institute of Technology
| - |
| Andrew C. Singer | M | - |
Massachusetts Institute of Technology
| 9 years |
| Argeris Karabelas | M | 71 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 4 years |
| David Southwell | M | 63 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 4 years |
| Michael Zhang | M | - |
Massachusetts Institute of Technology
| 11 years |
| Ioannis Kymissis | M | - |
Massachusetts Institute of Technology
| 9 years |
| Chantal Moore | F | - |
Massachusetts Institute of Technology
| 6 years |
| Alan Chhabra | M | - |
Massachusetts Institute of Technology
| 5 years |
| Yong Gang Ren | M | 59 |
Massachusetts Institute of Technology
| 5 years |
| Sung-Hwan Shin | M | 61 |
Massachusetts Institute of Technology
| 7 years |
| Catherine Corrigan | M | 55 |
Massachusetts Institute of Technology
| 5 years |
| Neil Renninger | M | 49 |
Massachusetts Institute of Technology
| 5 years |
| Warren Chen | M | - |
Massachusetts Institute of Technology
| 4 years |
| Georgios Alexopoulos | M | - |
Massachusetts Institute of Technology
| 5 years |
| Rob Burn | M | - |
Massachusetts Institute of Technology
| 5 years |
| Maria Staton | F | 54 |
Massachusetts Institute of Technology
| 2 years |
| Walid Fakhry | M | - |
Massachusetts Institute of Technology
| 6 years |
| Hákon Guðbjartsson | M | - |
Massachusetts Institute of Technology
| 5 years |
| Katie Hall | M | - |
Massachusetts Institute of Technology
| 9 years |
| Eran Egozy | M | - |
Massachusetts Institute of Technology
| 4 years |
| Bryan R. Smith | M | - |
Massachusetts Institute of Technology
| - |
| Andra Bolotin | F | 61 |
Massachusetts Institute of Technology
| 2 years |
| Scott A. Miller | M | - |
Massachusetts Institute of Technology
| 5 years |
| Tom Rikert | M | - |
Massachusetts Institute of Technology
| 5 years |
| Guo Zhong Xie | M | 64 |
Massachusetts Institute of Technology
| 4 years |
| Jonathan Paul Loflin | M | - |
Massachusetts Institute of Technology
| 5 years |
| Simo Kamppari | M | - |
Massachusetts Institute of Technology
| 4 years |
| Hongming Chen | M | 53 |
Massachusetts Institute of Technology
| 3 years |
| Dustin Byrne | M | - |
Massachusetts Institute of Technology
| 5 years |
| Reza Abhari | M | 62 |
Massachusetts Institute of Technology
| 3 years |
| Eric Oliver | M | - |
Massachusetts Institute of Technology
| 7 years |
| Craig Griffin | M | - |
Massachusetts Institute of Technology
| 5 years |
| Warren Chou | M | - |
Massachusetts Institute of Technology
| 6 years |
| Albert Wong | M | 61 |
Massachusetts Institute of Technology
| 3 years |
| Errol Arkilic | M | - |
Massachusetts Institute of Technology
| 6 years |
| Michael Minnich | M | 52 |
Massachusetts Institute of Technology
| 4 years |
| Thilo Semmelbauer | M | 58 |
Massachusetts Institute of Technology
| 2 years |
| Christopher J. Neil | M | 58 |
Massachusetts Institute of Technology
| 6 years |
| William Feehery | M | 54 |
Massachusetts Institute of Technology
| 5 years |
| Philippe Laffont | M | - |
Massachusetts Institute of Technology
| 6 years |
| Joe Schirripa | M | - |
Massachusetts Institute of Technology
| 6 years |
| Mike McElroy | M | - |
Massachusetts Institute of Technology
| 9 years |
| Walid Fakhry | M | - |
Massachusetts Institute of Technology
| 6 years |
| Ben Shih | M | - |
Massachusetts Institute of Technology
| 4 years |
| Gregory Lambrecht | M | - |
Massachusetts Institute of Technology
| 6 years |
| Matthias B. Jaffé | M | 50 |
Massachusetts Institute of Technology
| 3 years |
| Mihnea Moldoveanu | M | - |
Massachusetts Institute of Technology
| 5 years |
| Sami Shalabi | M | - |
Massachusetts Institute of Technology
| 5 years |
| Isai Peimer | M | 46 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 3 years |
| Benjamin van Roy | M | - |
Massachusetts Institute of Technology
| 6 years |
| Evren Ünver | M | - |
Massachusetts Institute of Technology
| 5 years |
| Adrianna Ma | F | 50 |
Massachusetts Institute of Technology
| 5 years |
| Kathy Chiu | F | - |
Massachusetts Institute of Technology
| 5 years |
| Michael A. Klug | M | - |
Massachusetts Institute of Technology
| 7 years |
| Ayman Mahmoud Hindy | M | - |
Massachusetts Institute of Technology
| 4 years |
| Jonathan Sheena | M | 51 |
Massachusetts Institute of Technology
| 6 years |
| Eve Phillips | F | - |
Massachusetts Institute of Technology
| 5 years |
| Mike Capelle | M | - |
Massachusetts Institute of Technology
| 2 years |
| Morten Westye Høegh | M | 51 |
Massachusetts Institute of Technology
| 4 years |
| Rick Grinnell | M | - |
Massachusetts Institute of Technology
| 5 years |
| Nicholas L. Abbott | M | - |
Massachusetts Institute of Technology
| 3 years |
| David A. Mindell | M | - |
Massachusetts Institute of Technology
| 4 years |
| Surya Ganguli | M | - |
Massachusetts Institute of Technology
| 5 years |
| Ira Jonathan Hochman | M | - |
Massachusetts Institute of Technology
| 4 years |
| Rahul Advani | M | - |
Massachusetts Institute of Technology
| 6 years |
| Ronald Schmelzer | M | - |
Massachusetts Institute of Technology
| 4 years |
| Pete O'Neill | M | - |
Massachusetts Institute of Technology
| 4 years |
| Harri K. Kytömaa | M | 65 |
Massachusetts Institute of Technology
| 8 years |
| John de Souza | M | - |
Massachusetts Institute of Technology
| 4 years |
| Danny Su | M | - |
Massachusetts Institute of Technology
| 4 years |
| Matthew Konosky | M | - |
Massachusetts Institute of Technology
| 4 years |
| Kathleen Chien | F | 54 |
Massachusetts Institute of Technology
| 4 years |
| Jory Bell | M | - |
Massachusetts Institute of Technology
| 5 years |
| Michael James Pascutti | M | - |
Massachusetts Institute of Technology
| 4 years |
| Thomas J. Cole | M | - |
Massachusetts Institute of Technology
| 4 years |
| Daisuke Uemura | M | - |
Massachusetts Institute of Technology
| 1 years |
| Taras Ivanenko | M | - |
Massachusetts Institute of Technology
| 5 years |
| J. Kim | M | 55 |
Massachusetts Institute of Technology
| 4 years |
| Alexis Black Bjorlin | M | 50 |
Massachusetts Institute of Technology
| 4 years |
| Subra Suresh | M | 67 |
Massachusetts Institute of Technology
| 20 years |
| Gregory Papadopoulos | M | 66 |
Massachusetts Institute of Technology
| 6 years |
| Hon Tang | M | 55 |
Massachusetts Institute of Technology
| 3 years |
| Eugene W. Harris | M | - |
Massachusetts Institute of Technology
| 1 years |
| Charles H. Fine | M | 67 |
Massachusetts Institute of Technology
| 8 years |
| Chris Turner | M | - |
Massachusetts Institute of Technology
| 4 years |
| Y. Jennifer Wang | F | - |
Massachusetts Institute of Technology
| 4 years |
| Marin Soljacic | M | - |
Massachusetts Institute of Technology
| 4 years |
| Mark R. Cox | M | 59 |
Massachusetts Institute of Technology
| 1 years |
| Edward O. Shaffer | M | - |
Massachusetts Institute of Technology
| 3 years |
| Joseph Bishop | M | - |
Massachusetts Institute of Technology
| 4 years |
| Jay Sarkar | M | - |
Massachusetts Institute of Technology
| 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 99 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Devang Vallabhdas Kantesaria
- Personal Network
